• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

The first Chinese guidelines on the Management of Ascites and its Related Complications in Cirrhosis: a great goal for a great country.

作者信息

Angeli P

机构信息

Internal Medicine and Hepatology Unit (UIMH), Dept of Medicine (DIMED), Padova University-Teaching Hospital, Padua, Italy.

出版信息

Hepatol Int. 2019 Jul;13(4):395-398. doi: 10.1007/s12072-019-09961-4. Epub 2019 Jul 16.

DOI:10.1007/s12072-019-09961-4
PMID:31313026
Abstract
摘要

相似文献

1
The first Chinese guidelines on the Management of Ascites and its Related Complications in Cirrhosis: a great goal for a great country.首部《中国肝硬化腹水及其相关并发症管理指南》：大国之伟大目标。
Hepatol Int. 2019 Jul;13(4):395-398. doi: 10.1007/s12072-019-09961-4. Epub 2019 Jul 16.
2
[Clinical guidelines for diagnosis and treatment of ascites. Therapeutic aspects of complicated ascites and hepatorenal syndrome].[腹水诊断与治疗临床指南。复杂性腹水和肝肾综合征的治疗方面]
Rev Gastroenterol Mex. 2009 Oct-Dec;74(4):396-8.
3
[Progress in the diagnosis and treatment of ascites in cirrhosis: introduction of EASL clinical practice guidelines on management of ascites in cirrhosis].[肝硬化腹水的诊断与治疗进展：欧洲肝脏研究学会肝硬化腹水管理临床实践指南介绍]
Zhonghua Gan Zang Bing Za Zhi. 2010 Dec;18(12):951-4. doi: 10.3760/cma.j.issn.1007-3418.2010.12.021.
4
[Guidelines for diagnosis and management of cirrhotic ascites and its complications. The Israeli Association for the Study of the Liver].[肝硬化腹水及其并发症的诊断与管理指南。以色列肝脏研究协会]
Harefuah. 2012 Dec;151(12):705-8, 719.
5
To salt or not to salt?-That is the question in cirrhosis.在肝硬化中，问题是要盐还是不要盐？
Liver Int. 2018 Jul;38(7):1148-1159. doi: 10.1111/liv.13750. Epub 2018 May 16.
6
Ascites in cirrhosis: pathophysiology and management.肝硬化腹水：病理生理学与管理
Br J Hosp Med. 1988 Oct;40(4):256, 258, 260-2.
7
[Clinical guidelines for diagnosis and treatment of ascites. Therapeutic aspects of management of uncomplicated ascites.].[腹水诊断与治疗临床指南。单纯性腹水管理的治疗方面。]
Rev Gastroenterol Mex. 2009 Oct-Dec;74(4):392-5.
8
[Therapeutic program for ascites. Recommendations from the Swedish Society of Gastroenterology and Gastrointestinal Endoscopy].[腹水治疗方案。瑞典胃肠病学和胃肠内镜学会的建议]
Lakartidningen. 2001 Dec 5;98(49):5649-52, 5655.
9
Management of refractory ascites.难治性腹水的管理
Clin Gastroenterol Hepatol. 2005 Dec;3(12):1187-91. doi: 10.1016/s1542-3565(05)00861-x.
10
Pathophysiology, complications, and treatment of ascites.腹水的病理生理学、并发症及治疗
Clin Liver Dis. 1997 May;1(1):129-55. doi: 10.1016/s1089-3261(05)70261-0.

引用本文的文献

1
Correlation between serum markers and transjugular intrahepatic portosystemic shunt prognosis in patients with cirrhotic ascites.肝硬化腹水患者血清标志物与经颈静脉肝内门体分流术预后的相关性
World J Gastrointest Surg. 2024 Feb 27;16(2):481-490. doi: 10.4240/wjgs.v16.i2.481.

本文引用的文献

1
Reply to: "Prophylaxis of spontaneous bacterial peritonitis: is there still room for quinolones?".回复：“自发性细菌性腹膜炎的预防：喹诺酮类药物还有空间吗？”
J Hepatol. 2019 May;70(5):1028-1030. doi: 10.1016/j.jhep.2019.01.011. Epub 2019 Feb 2.
2
Epidemiology and Effects of Bacterial Infections in Patients With Cirrhosis Worldwide.全球肝硬化患者细菌感染的流行病学和影响。
Gastroenterology. 2019 Apr;156(5):1368-1380.e10. doi: 10.1053/j.gastro.2018.12.005. Epub 2018 Dec 13.
3
Tolvaptan treatment improves survival of cirrhotic patients with ascites and hyponatremia.
托伐普坦治疗可提高伴有腹水和低钠血症的肝硬化患者的生存率。
BMC Gastroenterol. 2018 Sep 4;18(1):137. doi: 10.1186/s12876-018-0857-0.
4
Effects of Long-term Norfloxacin Therapy in Patients With Advanced Cirrhosis.长期诺氟沙星治疗对晚期肝硬化患者的影响。
Gastroenterology. 2018 Dec;155(6):1816-1827.e9. doi: 10.1053/j.gastro.2018.08.026. Epub 2018 Aug 23.
5
Midodrine and albumin for prevention of complications in patients with cirrhosis awaiting liver transplantation. A randomized placebo-controlled trial.米多君和白蛋白预防肝硬化等待肝移植患者并发症的随机安慰剂对照试验。
J Hepatol. 2018 Dec;69(6):1250-1259. doi: 10.1016/j.jhep.2018.08.006. Epub 2018 Aug 21.
6
Long-term albumin administration in decompensated cirrhosis (ANSWER): an open-label randomised trial.失代偿期肝硬化患者长期白蛋白治疗（ANSWER）：一项开放标签随机试验。
Lancet. 2018 Jun 16;391(10138):2417-2429. doi: 10.1016/S0140-6736(18)30840-7. Epub 2018 Jun 1.
7
Association Between Grade of Acute on Chronic Liver Failure and Response to Terlipressin and Albumin in Patients With Hepatorenal Syndrome.急慢性肝衰竭程度与肝肾综合征患者特利加压素和白蛋白反应的关系。
Clin Gastroenterol Hepatol. 2018 Nov;16(11):1792-1800.e3. doi: 10.1016/j.cgh.2018.01.035. Epub 2018 Jan 31.
8
Assessment of Sepsis-3 criteria and quick SOFA in patients with cirrhosis and bacterial infections.肝硬化合并细菌感染患者中 Sepsis-3 标准和快速 SOFA 的评估。
Gut. 2018 Oct;67(10):1892-1899. doi: 10.1136/gutjnl-2017-314324. Epub 2017 Aug 31.
9
Utility and safety of tolvaptan in cirrhotic patients with hyponatremia: A prospective cohort study.托伐普坦在肝硬化低钠血症患者中的有效性和安全性：一项前瞻性队列研究。
Ann Hepatol. 2017 Jan-Feb;16(1):123-132. doi: 10.5604/16652681.1226823.
10
Midodrine and tolvaptan in patients with cirrhosis and refractory or recurrent ascites: a randomised pilot study.米多君和托伐普坦治疗肝硬化伴难治性或复发性腹水患者：一项随机先导研究。
Liver Int. 2017 Mar;37(3):406-414. doi: 10.1111/liv.13250. Epub 2016 Oct 2.